Scrutiny over insulin pricing intensifies in Washington

Congressional scrutiny over insulin prices is intensifying as Senate Finance Committee Chairman Chuck Grassley (R-Iowa) and Ranking Member Ron Wyden (D-Ore.) asked three PBMs to explain their role in pricing insulin products.

In letters to the CEOs of Cigna Corp. (NYSE:CI), CVS Health Corp. (NYSE:CVS) and OptumRx, the senators requested information regarding the PBMs' business relationships with manufacturers, payers and pharmacies, as well as explanations for how the PBMs determine rebates and select products for formularies. OptumRx is the PBM and pharmacy care services unit of UnitedHealth Group Inc. (NYSE:UNH)...